| 臺大學術典藏 |
2021-09-01T02:02:06Z |
Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based Regimens
|
Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Tsai Y.-C.; Huang K.-H.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T01:54:33Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; Tsai Y.-C.; Huang K.-H.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T01:54:32Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
Lin C.-C.; Yeh K.-H.; Yang C.-H.; Hsu C.; Tsai Y.-C.; Hsu W.-L.; ANN-LII CHENG; Hsu C.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:32Z |
Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trial
|
Lin C.-C.; Hsu C.-H.; Hour T.-C.; ANN-LII CHENG; Huang C.-Y.; Huang K.-H.; Chen J.; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T01:54:29Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Lin Z.-Z.; Hsu C.; Chang Y.-C.; Yu C.-J.; Hsu C.-H.; Lin C.-C.; ANN-LII CHENG; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:29Z |
Weekly 24-hour infusional 5-fluorouracil as initial treatment for advanced gastric cancer with acute disseminated intravascular coagulation
|
Huang T.-C.; Yeh K.-H.; ANN-LII CHENG; Hsu C.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:27Z |
Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma
|
Lin C.-C.; Pu Y.-S.; Hsu C.-H.; Keng H.-Y.; ANN-LII CHENG; Yang C.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:26Z |
OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinoma
|
Gao M.; Yeh P.Y.; Lu Y.-S.; Hsu C.-H.; Chen K.-F.; Lee W.-C.; Feng W.-C.; Chen C.-S.; Kuo M.-L.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:25Z |
Disseminated peritoneal leiomyomatosis responds to systemic chemotherapy
|
Lin Y.-C.; Wei L.-H.; Shun C.-T.; ANN-LII CHENG; Hsu C.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:23Z |
The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma
|
Lin Z.-Z.; Hsu H.-C.; Hsu C.-H.; Yeh P.-Y.; Huang C.-Y.F.; Huang Y.-F.; Chen T.-J.; Kuo S.-H.; Hsu C.; Hu F.-C.; Jeng Y.-M.; Chung Y.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:22Z |
Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway
|
Chen K.-F.; Yeh P.-Y.; Hsu C.; Hsu C.-H.; Lu Y.-S.; Hsieh H.-P.; Chen P.-J.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:19Z |
Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder Cancer
|
Lin C.-C.; Hsu C.-H.; Cheng J.C.; Huang C.-Y.; Tsai Y.-C.; Hsu F.-M.; Huang K.-H.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T01:54:17Z |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
|
Hsu C.-H.; Shen Y.-C.; Lin Z.-Z.; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Hsu C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:16Z |
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
|
Hsu C.-H.; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; Lin Z.-Z.; Chao T.-Y.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:12Z |
Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
|
Shao Y.-Y.; Lin Z.-Z.; Hsu C.; Shen Y.-C.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:11Z |
Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma
|
Chiang C.-T.; Yeh P.-Y.; Gao M.; Chen C.-W.; Yeh L.-C.; Feng W.-C.; Kuo S.-H.; Hsu C.-H.; Lu Y.-S.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:10Z |
Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinoma
|
Shao Y.U.-Y.; Chen P.-J.; Lin Z.-Z.; Huang C.-C.; Ding Y.-H.; Lee Y.-H.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:10Z |
Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells
|
Chen K.-F.; Chen H.-L.; Tai W.-T.; Feng W.-C.; Hsu C.-H.; Chen P.-J.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:09Z |
Increasing incidence of brain metastasis in patients with advanced Hepatocellular carcinoma in the era of Antiangiogenic targeted therapy
|
Shao Y.-Y.; Lu L.-C.; ANN-LII CHENG; Hsu C.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:08Z |
Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001
|
Kuo S.-H.; Hsu C.-H.; Chen L.-T.; Lu Y.-S.; Lin C.-H.; Yeh P.-Y.; Jeng H.-J.; Gao M.; Yeh K.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:06Z |
High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy
|
Shao Y.-Y.; Lin Z.-Z.; Chen T.-J.; Hsu C.; Shen Y.-C.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:06Z |
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil
|
Hsu C.-Y.; Shen Y.-C.; Yu C.-W.; Hsu C.; Hu F.-C.; Hsu C.-H.; Chen B.-B.; Wei S.-Y.; ANN-LII CHENG; Shih T.T.-F. |
| 臺大學術典藏 |
2021-09-01T01:54:05Z |
Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: A Taiwan cooperative oncology group phase II study
|
Ch'Ang H.-J.; Lin Y.-L.; Wang H.-P.; Chiu Y.-F.; Chang M.-C.; Hsu C.-H.; Tien Y.-W.; Chen J.-S.; Hsieh R.-K.; Lin P.-W.; Shan Y.-S.; ANN-LII CHENG; Chang J.-Y.; Whang-Peng J.; Hwang T.-L.; Chen L.-T. |
| 臺大學術典藏 |
2021-09-01T01:54:05Z |
Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials
|
Yang S.-H.; Kuo Y.-H.; Tien Y.-W.; Hsu C.; Hsu C.-H.; Kuo S.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:04Z |
T(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement
|
Kuo S.-H.; ANN-LII CHENG; Lin C.-W.; Hsu C.-H.; Wu M.-S.; Yeh K.-H.; Tzeng Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2021-09-01T01:54:02Z |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma
|
Shao Y.-Y.; Lin Z.-Z.; Hsu C.; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:53:58Z |
Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy
|
Shao Y.-Y.; Huang C.-C.; Lin S.-D.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:53:58Z |
Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma
|
Shau W.-Y.; Shao Y.-Y.; Yeh Y.-C.; Lin Z.-Z.; Kuo R.; Hsu C.-H.; Hsu C.; ANN-LII CHENG; Lai M.-S. |
| 臺大學術典藏 |
2021-09-01T01:53:57Z |
Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer
|
Lu L.-C.; Shao Y.-Y.; Hsu C.-H.; Hsu C.; Cheng W.-F.; Lin Y.-L.; ANN-LII CHENG; Yeh K.-H. |
| 臺大學術典藏 |
2021-09-01T01:53:56Z |
Dissimilar immunohistochemical expression of ERK and AKT between paired biopsy and hepatectomy tissues of hepatocellular carcinoma
|
Shao Y.-Y.; Chen C.-L.; Ho M.-C.; Huang C.-C.; Tu H.-C.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:53:55Z |
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems
|
Shao Y.-Y.; Lu L.-C.; Lin Z.-Z.; Hsu C.; Shen Y.-C.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:53:53Z |
The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinoma
|
Shao Y.-Y.; Chang Y.-L.; Huang C.-Y.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:53:49Z |
Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma
|
Lu L.-C.; Shao Y.-Y.; Kuo R.N.C.; Lin Z.-Z.; Yeh Y.-C.; Shau W.-Y.; Hsu C.-H.; ANN-LII CHENG; Lai M.-S. |
| 臺大學術典藏 |
2021-09-01T01:53:47Z |
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study
|
Hsu C.-H.; Kang Y.K.; Yang T.-S.; Shun C.-T.; Shao Y.-Y.; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; Hsu C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:53:46Z |
Nuclear expression of glioma-associated oncogene homolog 1 and nuclear factor-κb is associated with a poor prognosis of pancreatic cancer
|
Yang S.-H.; Hsu C.-H.; Lee J.-C.; Tien Y.-W.; Kuo S.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:53:45Z |
A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy
|
Shao Y.-Y.; Liang P.-C.; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Hsu C.; ANN-LII CHENG; Lin Z.-Z. |
| 臺大學術典藏 |
2021-09-01T01:53:45Z |
Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy
|
Chen W.-W.; Lin C.-C.; Huang T.-C.; ANN-LII CHENG; Yeh K.-H.; Hsu C.-H. |
| 臺大學術典藏 |
2021-09-01T01:53:44Z |
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study
|
Johnson P.J.; Qin S.; Park J.-W.; Poon R.T.P.; Raoul J.-L.; Philip P.A.; Hsu C.-H.; Hu T.-H.; Heo J.; Xu J.; Lu L.; Chao Y.; Boucher E.; Han K.-H.; Paik S.-W.; Robles-Avi?a J.; Kudo M.; Yan L.; Sobhonslidsuk A.; Komov D.; Decaens T.; Tak W.-Y.; Jeng L.-B.; Liu D.; Ezzeddine R.; Walters I.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:53:43Z |
Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size
|
Lin Z.-Z.; Shau W.-Y.; Hsu C.; Shao Y.-Y.; Yeh Y.-C.; Kuo R.N.-C.; Hsu C.-H.; Yang J.C.-H.; ANN-LII CHENG; Lai M.-S. |
| 臺大學術典藏 |
2021-09-01T01:53:42Z |
Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy
|
Lu L.-C.; Shao Y.-Y.; Chan S.-Y.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:42:28Z |
�]-Catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma
|
Lu L.-C.; Shao Y.-Y.; Lee Y.-H.; Hsieh M.-S.; Hsiao C.-H.; Lin H.-H.; Kao H.-F.; Ma Y.-Y.; Yen F.-C.; ANN-LII CHENG; Hsu C.-H. |
| 臺大學術典藏 |
2021-08-31T06:42:27Z |
Long-term disease-free survival achieved by anti-angiogenic therapy plus surgery in a hepatocellular carcinoma patient with extensive liver involvement and lung metastases
|
Shao Y.-Y.; Ho M.-C.; ANN-LII CHENG; Hsu C.-H. |
| 臺大學術典藏 |
2021-08-31T06:42:23Z |
Clinical activity of metronomic chemotherapy in liver cancers
|
Shao Y.-Y.; ANN-LII CHENG; Hsu C.-H. |
| 臺大學術典藏 |
2021-08-31T06:42:23Z |
Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy
|
Shao Y.-Y.; Wu C.-H.; Lu L.-C.; Chan S.-Y.; Ma Y.-Y.; Yen F.-C.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:42:22Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C.; Su W.-C.; Yen C.-J.; Hsu C.-H.; Su W.-P.; Yeh K.-H.; Lu Y.-S.; ANN-LII CHENG; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-08-31T06:42:19Z |
Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-analysis of randomized clinical trials
|
Shao Y.-Y.; Shau W.-Y.; Chan S.-Y.; Lu L.-C.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:49Z |
Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?
|
Shao Y.-Y.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:49Z |
Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan
|
Shao Y.-Y.; Hsu C.-H.; Yeh K.-H.; Chen H.-M.; Yeh Y.-C.; Lai C.-L.; Lin Z.-Z.; ANN-LII CHENG; Lai M.-S. |
| 臺大學術典藏 |
2021-08-31T06:29:49Z |
High serum transforming growth factor-�]1 levels predict outcome in hepatocellular carcinoma patients treated with sorafenib
|
Lin T.-H.; Shao Y.-Y.; Chan S.-Y.; Huang C.-Y.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:48Z |
Postchemoradiotherapy pathologic stage classified by the American joint committee on the cancer staging system predicts prognosis of patients with locally advanced esophageal squamous cell carcinoma
|
Guo J.-C.; Huang T.-C.; Lin C.-C.; Hsieh M.-S.; Chang C.-H.; Huang P.-M.; Lee J.-M.; Hsu F.-M.; Cheng J.C.-H.; Wang H.-P.; Yeh K.-H.; ANN-LII CHENG; Hsu C.-H. |
